A study to evaluate the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus (VEEV) DNA vaccine in an aerosol model of nonhuman primate infection was performed. Cynomolgus macaques vaccinated with a plasmid expressing the 26S structural genes of VEEV subtype IAB by particle-mediated epidermal delivery (PMED) developed virus-neutralizing antibodies. No serum viremia was detected in two out of three macaques vaccinated with the VEEV DNA after aerosol challenge with homologous virus, while one displayed a low viremia on a single day postchallenge. In contrast, all three macaques vaccinated with empty vector DNA developed a high viremia that persisted for at least 3 days after challenge. In addition, macaques vaccinated with the VEEV DNA had reduced febrile reactions, lymphopenia, and clinical signs of disease postchallenge as compared to negative control macaques. Therefore, although the sample size was small in this pilot study, these results indicate that a VEEV DNA vaccine administered by PMED can at least partially protect nonhuman primates against an aerosol VEEV challenge.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2010.09.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A multi-epitope self-amplifying mRNA SARS-CoV-2 vaccine design using a reverse vaccinology approach.
Res Pharm Sci
October 2024
School of Life Sciences and Technology, Institut Teknologi Bandung, Jalan Ganesa 10, Bandung 40132, Indonesia.
Background And Purpose: Massive vaccine distribution is a crucial step to prevent the spread of SARS-CoV2 as the causative agent of COVID-19. This research aimed to design the multi-epitope self-amplifying mRNA (saRNA) vaccine from the spike and nucleocapsid proteins of SARS-CoV2.
Experimental Approach: Commonly distributed constructions class I and II alleles of the Indonesian population were used to determine peptide sequences that trigger this population's high specificity T-cell response.
A Lipid Nanoparticle-Formulated Self-Amplifying RNA Rift Valley Fever Vaccine Induces a Robust Humoral Immune Response in Mice.
Vaccines (Basel)
September 2024
Department of Infectious Diseases, Imperial College London, Norfolk Place, London W2 1PG, UK.
Rift Valley fever (RVF) is a mosquito-borne viral zoonosis that causes high fetal and neonatal mortality rates in ruminants and sometimes severe to fatal complications like encephalitis and hemorrhagic fever in humans. There is no licensed RVF vaccine for human use while approved livestock vaccines have suboptimal safety or efficacy. We designed self-amplifying RNA (saRNA) RVF vaccines and assessed their humoral immunogenicity in mice.
View Article and Find Full Text PDFReplication of the Venezuelan Equine Encephalitis Vaccine from a Synthetic PCR Fragment.
Pharmaceutics
September 2024
Medigen, Inc., Frederick, MD 21701, USA.
Article Synopsis
- No approved human vaccine exists for Venezuelan equine encephalitis (VEE), which is caused by the VEE virus (VEEV).
- The study employed high-fidelity PCR to create synthetic fragments of the VEEV genome to aid in developing a live virus vaccine.
- Results showed that very small amounts of these synthetic fragments could successfully initiate the replication of the vaccine virus in cell cultures, suggesting a potential new method for vaccine development against VEE and other viruses.
Evaluation of bird-adapted self-amplifying mRNA vaccine formulations in chickens.
Vaccine
April 2024
Laboratory of Virology, Wageningen University & Research, Droevendaalsesteeg 1, Wageningen 6708PB, the Netherlands. Electronic address:
Article Synopsis
- Each year, millions of poultry are affected by avian influenza and infectious bursal disease, necessitating effective vaccines for prevention and control.
- Conventional vaccines often lack adequate safety and efficacy, highlighting the need for advanced vaccine platforms like self-amplifying RNA vaccines.
- This study explored Tembusu virus replicons, which showed better performance in expressing antigens and eliciting immune responses in chickens compared to the conventional Venezuelan equine encephalitis virus replicons.
Improved DNA Vaccine Delivery with Needle-Free Injection Systems.
Vaccines (Basel)
January 2023
PharmaJet, 400 Corporate Circle, Unit N, Golden, CO 80401, USA.
DNA vaccines have inherent advantages compared to other vaccine types, including safety, rapid design and construction, ease and speed to manufacture, and thermostability. However, a major drawback of candidate DNA vaccines delivered by needle and syringe is the poor immunogenicity associated with inefficient cellular uptake of the DNA. This uptake is essential because the target vaccine antigen is produced within cells and then presented to the immune system.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!